Israel’s InovyTec Medical Solutions Ltd. said Monday it received a $3 million investment for a 15 percent stake in the company from Vincent Medical Holdings, a Chinese holding company that does research and development and manufacture and sale of medical devices.
The investment will open up the Chinese market to InovyTec, the startup said. InovyTec has developed noninvasive and portable medical devices for out-of-hospital emergencies that aim to help even non-trained personnel provide life-saving emergency care to patients.
Leveraging Vincent Medical’s experience and presence in China, InovyTec will be able to “capitalize on the huge potential that exists in China and in the area in the sector of medical devices,” said Udi Cantor, the founder and CEO of the Israeli firm.
The startup’s LUBO product, which has already obtained the necessary regulatory permits, including from the FDA, allows the opening of the airways in a safe and noninvasive way based on the field experience of an Israeli army veteran, Dr. Omri Lubovski. A veteran of Israel’s aviation rescue 669 unit, Lubovski realized the need for opening the airway in a noninvasive, quick and efficient manner, especially in complicated field or road situations.
In addition, Inovytec has developed the SALI, a portable device that can treat both cardiac and respiratory failures by allowing emergency responders to manage airways, oxygen therapy and defibrillation on site, and at the same time transmit signals and data to any remote emergency center for backup using cloud technology.
“Vincent Medical is committed to support innovative products and identify relevant opportunities around the world, to increase the scope of products it offers,” said Vincent Choi, the founder of Vincent Medical, whose shares are traded on the Hong Kong stock exchange, said in a statement. “This strategic investment will allow us to expand our portfolio of products for use in cases where emergency care is needed in cardiology events or for opening up the airways.”
The Chinese investment follows that of German medical firm Rhon Klinikum, from which InovyTec raised $2 million.
The Times of Israel covers one of the most complicated, and contentious, parts of the world. Determined to keep readers fully informed and enable them to form and flesh out their own opinions, The Times of Israel has gradually established itself as the leading source of independent and fair-minded journalism on Israel, the region and the Jewish world.
We've achieved this by investing ever-greater resources in our journalism while keeping all of the content on our site free.
Unlike many other news sites, we have not put up a paywall. But we would like to invite readers who can afford to do so, and for whom The Times of Israel has become important, to help support our journalism by joining The Times of Israel Community. Join now and for as little as $6 a month you can both help ensure our ongoing investment in quality journalism, and enjoy special status and benefits as a Times of Israel Community member.